Technology:
   Repligen's Experimental Drug
Heparin often is administered to patients before heart
surgery to prevent dangerous blood clots from forming.
   Repligen recently formed a $45 million research and
development partnership to develop platelet factor-4 as a
treatment for certain cancers and other disorders.